Applied DNA Sciences, Inc. today announced the award of a contract from HDT Bio in support of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio.
The project aims to facilitate the rapid production of vaccines during outbreaks/pandemics, focusing on decentralized vaccine manufacturing, with vaccines deemed critical medical countermeasures to infectious disease threats.
Under the terms of the contract, Applied DNA will supply Linea DNA IVT templates to HDT Bio for use in conjunction with its LION formulated repRNA (self-replicating RNA) vaccination platform.
The Linea DNA platform is a completely cell-free DNA production platform founded on Applied DNA’s long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
Source: Applied DNA, adapted